Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > July 2013 - Volume 29 - Issue 7 > Xenon-related Analgesia: A New Target for Pain Treatment
Clinical Journal of Pain:
doi: 10.1097/AJP.0b013e31826b12f5
Review Articles

Xenon-related Analgesia: A New Target for Pain Treatment

Giacalone, Marilù MD; Abramo, Antonio MD; Giunta, Francesco MD; Forfori, Francesco MD

Collapse Box

Abstract

The noble gas xenon has been known for >50 years in the field of anesthesia with an emerging series of favorable features; several clinical and preclinical studies performed over the last years reveal a renewed interest because they substantially agree on attributing relevant analgesic properties to xenon. The main mechanism of action is the inhibition of N-methyl-d-aspartate receptors of glutamate; it involves the blocking of painful stimuli transmissions from peripheral tissues to the brain and it also avoids the development of pain hypersensitivity. Therefore, this mechanism is responsible for the inhibition of pain transmission at spinal and supraspinal levels, as well as the cortical level. In all these levels of pain pathways, as the development of hyperalgesia is possible, xenon efficacy can also be based on the blocking of these processes. Several forms of pain share such mechanisms in their maintenance, and xenon can be successfully used at low dosages, which have no effects on vital parameters. The literature shows that analgesic features could also emerge outside the field of anesthesia; thus, this could permit xenon to have a larger usage according to local availability.

Copyright © 2013 by Lippincott Williams & Wilkins

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.